<DOC>
	<DOCNO>NCT00002166</DOCNO>
	<brief_summary>To provide access Viramune evaluate tolerance safety Viramune patient progressive , symptomatic HIV disease fail intolerant currently approve treatment HIV-1 infection unable participate another Viramune control clinical trial compel need anti-HIV treatment .</brief_summary>
	<brief_title>An Open-Label , Non-Randomized Trial Evaluate Tolerability Safety Viramune ( Nevirapine ) Adult Pediatric Patients With Progressive HIV Disease</brief_title>
	<detailed_description>Eligible adult patient ( &gt; = 13 year age ) receive treatment Viramune daily 2 week twice daily . Eligible pediatric patient ( &lt; 13 year age ) receive low dose Viramune daily 2 week twice daily . All patient receive Viramune without concomitant antiretroviral therapy . Patients evaluate week 2 , 4 , 8 , 16 , 24 , 32 every 8 week thereafter . PER AMENDMENT 01/31/97 : Enrollment close adult patient . As 1/31/97 enrol pediatric patient .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Inclusion Criteria Patients must : Patients &gt; 18 month age history positive serology HIV1 infection patient &lt; = 18 month age history positive viral culture , detectable p24 antigen , positive peripheral blood mononuclear cell macro culture . Patients &gt; = 13 year age CD4+ cell count &lt; = 200 cells/mm3 . Patients &lt; 13 year age CD4 % &lt; = 14 % 50 % decrease CD4 % past 6 month previous CD4 % &gt; =20 % . Patient fail intolerant currently approve treatment HIV1 infection unable participate control viramune clinical trial . Written inform consent parent guardian patient &lt; 18 year age . Patient guardian willing able follow protocol requirement . ( PER AMENDMENT 1/29/97 : Enrollment close adult , Jan. 29th pediatric patient enrol . ) Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Patient qualifies participation actively accrue Viramune control clinical trial . Concurrent Medication : Excluded : Dicumarol , Warfarin , anticoagulant medication . Tolbutamide . Investigational drug , protease inhibitor , nonnucleoside transcriptase inhibitor . Neurotoxic drug . Cimetidine . Erythromycin . Required : Patient fail intolerant currently approve treatment HIV1 infection .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2002</verification_date>
	<keyword>Nevirapine</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>